|
|
Upfront Briefing
GSK bought Nuvalent for $10.6B and had an FDA approval eight days later — Jideytro cleared for ROS1-positive NSCLC, roughly two months ahead of its September action date. That is a fast payback on the largest oncology cheque GSK has written in years, and the ALK follow-on is queued for November. Arrowhead's plozasiran ran two Phase 3s to 79% and 81% triglyceride cuts and wiped out pancreatitis events in the highest-risk group. Roche, meanwhile, delivered the boring kind of good: CHF 30.4B, guidance untouched.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,499.0 |
(0.1%) |
+9.3% |
| Nasdaq 100 |
28,998.1 |
(0.5%) |
+15.0% |
| Russell 2000 |
2,959.9 |
(0.9%) |
+18.0% |
| Healthcare (XLV) |
159.4 |
(0.5%) |
+2.5% |
| Biotech (XBI) |
152.1 |
(1.5%) |
+25.2% |
| Nasdaq Biotech (NBI) |
6,470.7 |
(1.2%) |
+13.4% |
| Clinical Trials (BBC) |
50.6 |
(1.6%) |
+34.5% |
|
- Biotech lagged the tape with XBI (1.5%) and NBI (1.2%), a de-risking session ahead of a heavy earnings slate — Roche, argenx and Samsung Biologics all reported into the following morning.
- Crude did the damage: Brent settled +3.4% at $94.07 and WTI +3% at $86.83 on the 11th round of US strikes against Iran and Houthi threats to Red Sea shipping, pushing the 10Y to 4.66% and capping risk appetite ahead of after-hours Alphabet and Tesla prints.
- Market data: U.S. cash close Wednesday, 22 July 2026.
The Big 3
|
1
|
FDA clears GSK's Jideytro eight days after $10.6B Nuvalent close
|
- The FDA approved Jideytro (zidesamtinib) for previously treated ROS1-positive NSCLC, roughly two months ahead of its 18 September action date and eight days after GSK closed its $10.6B Nuvalent acquisition.
- Why it matters: ARROS-1 put up 44% ORR in 117 pretreated patients with 48% intracranial response — the second number is the one that sells, because CNS progression is the standard failure mode in ROS1 and the pitch against BMS's Augtyro and Nuvation's Ibtrozi in second line. GSK's first lung cancer approval, on an asset it has owned for a week. But ROS1 is a small pool; the Nuvalent price gets justified by neladalkib in ALK-altered NSCLC, PDUFA 27 November, where the addressable population is several times larger. Watch that date, not this one.
- Source: BioPharma Dive
|
|
2
|
Arrowhead's plozasiran cuts triglycerides 81% across two Phase 3s
|
- SHASTA-3 and SHASTA-4 both hit, with median triglyceride reductions of 79% and 81% at month 12 versus roughly 27% on placebo, plus a statistically significant cut in acute pancreatitis events.
- Why it matters: Two Phase 3s, roughly 750 patients, and the endpoint that writes the label is pancreatitis — down 78% pooled and 100% in the >880 mg/dL prior-event group. Quarterly dosing is the commercial wedge against Ionis's monthly olezarsen in the same sHTG chase, and Arrowhead already has Redemplo's FCS launch infrastructure and pricing model built to carry a broader indication. sNDA lands before year-end, with ESC on 30 August as the data checkpoint. The soft spot: 100% event reduction in a small high-risk subgroup rests on single-digit event counts, and that number will get stress-tested when the full dataset is on screen.
- Source: BioPharma Dive
- More: BioPharm International; Arrowhead
|
| 3 | Roche holds guidance on CHF 30.4B first half, +6% CER |
-
Roche posted H1 2026 group sales of CHF 30.4B, +6% at constant exchange rates and (2%) in CHF on franc strength, and confirmed its full-year mid-single-digit sales and high-single-digit core EPS outlook.
-
Why it matters:
Core operating profit ran +10% CER to CHF 11.9B against +6% sales — operating leverage, not just volume, and the reason core EPS came in at +9% CER. Pharma did CHF 23.6B on Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo. The (2%) CHF line is translation, and management chose to leave guidance untouched rather than trim it, which is what the desk wanted after Q1's (5%) CHF optics. Two things to keep an eye on: Diagnostics at +3% CER is still absorbing China pricing reform, and Xolair meets its first biosimilar in H2 — guidance already carries roughly CHF 1B of LOE drag for the year.
-
Source:
Roche
|
Everything Else that broke
- Vertex was reportedly the sole bidder in its high-premium Crinetics acquisition. — BioPharma Dive
- WuXi AppTec's injunction fight may turn on whether the court sees irreparable harm. — BioCentury
- argenx booked $1.5B in Q2 global product net sales, up 60% year over year and 17% sequentially, with the ALKIVIA myositis readout on track for 3Q26. — argenx
- Celldex scrapped barzolvolimab in prurigo nodularis after the Phase 2 missed its Week 12 WI-NRS endpoint and all key secondaries — deep mast cell depletion on tryptase, no effect on itch or lesions. CSU Phase 3 topline still due September/October. — Endpoints
- Samsung Biologics reported Q2 revenue of KRW 1,321B and operating profit of KRW 586B. — PR
- CLINUVEL will move its headquarters to the U.S. effective 1 January 2027. — PR
- The House passed the FDA Modernization Act 3.0 (H.R. 2821), directing the FDA to strip animal-testing language from its regulations; the Senate passed the same language in December 2025 and must now clear the House version. — Fierce Biotech
- HHS aligned with the administration's $5B Genesis Mission on AI, centred on an NIH-led Bio Genesis Mission for biomedical research. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Nona Biosciences partnered with the Medical University of Vienna on fully human infectious-disease antibodies. — PR
- Royalty Pharma paid Neurimmune $125M upfront, up to $425M total, for a slice of sales on cliramitug — the AstraZeneca-partnered ATTR amyloidosis antibody — adding a second transthyretin royalty to its book. — Fierce Biotech
VC / Private Financings
- Crystalys Therapeutics raised a $130M Series B to push gout candidate dotinurad through Phase 3 and prepare for launch; syndicate not fully disclosed. — Fierce Biotech
- Tikva Allocell closed an $8M Series A to advance its engineered EBV-specific T-cell therapy for solid tumors; lead investor: Kantharos Capital. — PR
IPOs / Follow-Ons
Academic Corner - A Nature Biotechnology paper used single-cell spatial transcriptomics to map tumor neoantigen recognition and immune niches. — Nature Biotech
- Phase 1 data for cevostamab in relapsed or refractory multiple myeloma showed no maximum tolerated dose reached. — Nature Medicine
- NEJM published a clinicopathological case of a 28-year-old man with headache and monocular vision loss. — NEJM
|
|
Eight days from close to approval. Somewhere in GSK's BD team, someone is asking for a raise.
— BioBucks Team
|
|
|
